垂体手术未治愈的库欣病患者的药物治疗中断情况
该回顾性研究纳入119例首次经蝶窦手术治疗的库欣病患者中的36例未治愈者,评估药物治疗的长期持续性和中断率。药物治疗在29例中启用,79%至少一次尿游离皮质醇正常,但62%在末次随访前中断,仅38%获长期控制;二次经蝶窦手术、双侧肾上腺切除术和垂体放疗的最终治疗成功率分别为50%、100%和0%。
要点
- 药物治疗在29/36例(81%)中启用,79%至少一次UFC正常,但62%中断,仅38%获长期控制。
- 二次经蝶窦手术最终治疗成功8/16(50%),双侧肾上腺切除术14/14(100%),垂体放疗0/5。
- 已发表试验中药物治疗1年中断率11%~51%,5年前中断率32%~74%。
核心结论
- 药物治疗使23/29例(79%)至少一次UFC正常,但仅11/29例(38%)获长期控制,中断率高,与已发表数据相似。
- 5例因成功的二次经蝶窦手术而中断有效且耐受良好的药物治疗。
- 进一步研究将显示不同皮质醇合成抑制剂策略能否降低不适合二次经蝶窦手术患者的中断率,从而避免双侧肾上腺切除术。
研究设计与样本
- 回顾性研究,在优先二次经蝶窦手术的中心进行。
- 纳入119例首次经蝶窦手术治疗的库欣病患者中的36例,包括19例手术失败和17例复发。
- 平均随访6.1年(95%CI 5.27-6.91)。
- 控制定义为尿游离皮质醇(UFC)正常化,最终治疗定义为末次随访时允许控制的治疗。
- 分析已发表库欣病前瞻性临床试验中药物治疗的中断率。
主要发现
- 33/36例(92%)达到控制。
- 药物治疗在29/36例(81%)中启用,23/29例(79%)至少一次UFC正常,18/29例(62%)在末次随访前中断。
- 药物治疗为最终治疗者11/29例(38%),均使用皮质醇合成抑制剂。
- 二次经蝶窦手术为最终治疗8/16例(50%),双侧肾上腺切除术14/14例(100%),垂体放疗0/5例。
- 已发表试验中,药物治疗1年中断率11%~51%,5年前中断率32%~74%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: When transsphenoidal surgery (TSS) does not cure Cushing's disease (CD), 4 treatments are available: drug treatment (DT), second TSS (2nd TSS), bilateral adrenalectomy (BA), and pituitary radiotherapy (PR). DT is attractive but supposes long-term continuation, which we aimed to evaluate. DESIGN AND METHODS: Retrospective study, in a center prioritizing 2nd TSS, of 36 patients, including 19 with TSS failure and 17 with recurrence, out of 119 patients with CD treated by a first TSS, average follow-up 6.1 years (95% confidence interval 5.27-6.91). Control was defined as normalization of urinary free cortisol (UFC) and final treatment (FT) as the treatment allowing control at last follow-up. We also analyzed discontinuation rates of DT in published CD prospective clinical trials. RESULTS: Control was achieved in 33/36 patients (92%). DT was initiated in 29/36 patients (81%), allowing at least 1 normal UFC in 23/29 patients (79%) but was discontinued before last follow-up in 18/29 patients (62%). DT was FT in 11/29 patients (38%), all treated with cortisol synthesis inhibitors. Second TSS was FT in 8/16 (50%), BA in 14/14 (100%), and PR in 0/5. In published trials, discontinuation of DT was 11% to 51% at 1 year and 32% to 74% before 5 years. CONCLUSION: DT allowed at least 1 normal UFC in 23/29 patients (79%) but obtained long-term control in only 11/29 (38%), as discontinuation rate was high, although similar to published data. Interestingly, a successful 2nd TSS was the cause for discontinuing efficient and well-tolerated DT in 5 patients. Further studies will show whether different strategies with cortisol synthesis inhibitors may allow for a lower discontinuation rate in patients not candidates for a 2nd TSS so that BA may be avoided in these patients.
引用
- Ghalawinji A, Drezet L, Chaffanjon P, et al. Discontinuation of Drug Treatment in Cushing's Disease Not Cured by Pituitary Surgery. J Clin Endocrinol Metab. 2024. PMID: 37962981. doi:10.1210/clinem/dgad662
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。